Hemlibra®
HEMLIBRA® (emicizumab-kxwh) injection, for subcutaneous use is a bispecific factor IXa- and factor X-directed antibody indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.
For indications, dosing and other information, please refer to the prescribing information.